Epocrates narrows market research to target pharmas

Share this article:

Athenahealth has wasted little time in putting its mark on Epocrates.

The electronic health records and practice management giant finalized its acquisition of mobile health firm Epocrates just last week, but has already eliminated part of its market research business which offered marketing research firms access to its physician panels. Eight of those employees were promptly hired by MDLinx owner M3 Global Research, an Epocrates partner. The M3 hires included former Epocrates market research lead Sheryl Lowenhar.

“As part of the merger, we've been taking a look at all of our initiatives to see what fits strategically,” said Healther Gervais, SVP commercial operations at Epocrates. “At its center, that's helping caregivers make good decisions, and we decided that being a broker didn't meet our needs, so we're discontinuing those services.”

Gone is the company's QuickRecruit business, whereby research firms doing surveys could buy access to Epocrates' physician panels. The company will keep its insight analytical platform, which caters to Wall Street analysts seeking market insights and to pharmas wanting basic message testing and segmentation in a hurry.

Epocrates will continue to honor existing QuickRecruit contracts, said Gervais, but won't take on new clients for it.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...